*Agenda subject to change

08.45am - 09.25am - Delegates Registration

09.30am - Chair's Welcome & Introduction

Doris-Ann Williams, Chief Executive, BIVDA - Confirmed

09.40am - The Role of Diagnostics in Prevention

Fiona Carragher, Deputy Chief Scientific Officer, NHS England- Confirmed

09.55am - How the NICE Office for Market Access (OMA) can help the life sciences industry – Overview of OMA services

Ben Hendry, Outreach and Engagement Manager, NICE Office for Market Access-Confirmed

10.15am - How Diagnostics Are Being Used to Treat Children

Dr Ann Van den Bruel, Associate Professor, Department of Primary Care Health Sciences; Director of the NIHR Diagnostic Evidence Cooperative, Oxford - Confirmed

10.35am - Expanding Diagnostic Capacity - Multi-disciplinary Rapid Diagnostic and Assessment Centres

Dr Wai Lup Wong, Consultant Radiologist, East and North Hertfordshire NHS Trust and Chair, Cancer Diagnostics CRG- Confirmed

10.55am - A Novel Biomarker for the Determination of Viral Etiology in Febrile Illnesses

Dr Robert Sambursky, Chairman, RPS - Confirmed

11.15am- The business case for Diagnostics

Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre London School of Hygiene & Tropical Medicine- Confirmed

11.30am - Refreshments

11:50am - Workshop Session 1

A series of workshops on six key health issues for which Diagnostics are being utilised. These workshops will provide a hands-on, intensive discussion forum on how to improve outcomes via Diagnostics

Workshop 1 - Sexual Health - Provided by Atlas Genetics - Multiplex STI POC Testing: Patient Benefits and Opportunities for Adoption
    Current turnaround times for sexually transmitted infections diagnosed by nucleic acid tests are typically four days or longer. This exacerbates the risk of onward transmission, loss to follow up and an increased risk of sequelae, and consequently, symptomatic and high-risk patients are often prescribed antibiotic treatment empirically.

    Four key STI pathogens, Chlamydia, Gonorrhoea, Trichomonas and Mycoplasma, often cause similar symptoms but require very different treatments, so inappropriate empirical treatment is a common problem. This workshop will describe a potential solution to diagnose these four key pathogens at the POC, examine the impact on patient health, patient management and also discuss the opportunities and barriers to adoption for this type of test.
Workshop 2 - Antibiotic Resistance - Provided by Abbott (formerly Alere) - Reducing Prescribing Through POC Rapid Diagnostics
    Antimicrobial resistance remains one of the biggest challenges facing the NHS. This workshop will see Professor Jonathan Cooke present the latest data regarding CRP rapid Point of Care testing and how this can support clinical and economic decision making. Finally there will be an opportunity to discuss and get hands on with Abbott's rapid diagnostic- Afinion2 which provides rapid, Lab quality, CRP, HbA1c, Lipids and ACR results
Workshop 3 - Diabetes - Provided by Johnson & Johnson - A Paradigm Shift in the Value Offered by Self Monitoring of Blood Glucose (SMBG)
    Diagnostics have a long history in supporting patients with diabetes. Currently, the criteria used to select blood glucose monitoring systems may be based on insignificant minor differences. Little value may be perceived in blood glucose monitoring. Evidence based outcomes to differentiate the systems have been scarce. Now comes a paradigm shift: A novel SMBG platform demonstrates how colours, pattern recognition, and a mobile digital application can help patients understand their blood sugar measurements and engage in remote consultations with their Healthcare provider. This platform is supported by evidence. Let's discuss: What are the opportunities and challenges in adopting this innovation?
    Facilitator: Nigel Morgan, Medical Lead United Kingdom & Ireland, Johnson & Johnson Diabetes Care Companies

12:20pm - Workshop Session 2

Workshop 4 - Sepsis - Provided by Momentum BioScience - Can we improve antimicrobial stewardship in suspected neonatal sepsis
    Up to 90% of patients suspected of sepsis are administered IV antibiotics and are confirmed negative for a bloodstream infection at 5-days.

    How can we improve this situation and support better antimicrobial stewardship as outlined in the O’Neill report 2016? O’Neill calls for a rapid test to rule out bacteria or fungi in blood cultures, so reducing time to conclude that a negative result is real and offering the chance to reduce the length of unnecessary antibiotic treatment by several days.

    Dr Elizabeth Pilling will take us through a study highlighting how we can deal with this challenge today
    Facilitator: Dr Elizabeth Pilling, Neonatologist at the Jessop Wing, Sheffield Teaching Hospitals
Workshop 5 & 6 Home Care Diagnostics & Cancer - Provided by Croydon University Hospital - The FIT revolution: coming to a GP practice near you
    The FIT revolution: coming to a GP practice near you

    FIT is a simple test which detects blood in stool. The test can give qualitative (yes/no) or quantitative faecal haemoglobin (F-Hb) readings. While some degree of gastrointestinal bleeding is physiological, F-Hb concentration is related to the severity of disease, and highest in colorectal cancer.

    A small pilot study was carried out in Croydon University Hospital to assess the effectiveness of FIT in patients with bowel symptoms referred under the 2 week rule with suspected cancer. The study showed that FIT can reduce the need for the more expensive and time consuming colonoscopy by as much as 80%.

    We are conducting a regional and national multicentre study to confirm these results, expected to report at the end of 2018. If proven this could herald a revolution in the way we manage bowel symptoms, saving patients' time in attending hospital appointments and the NHS millions.
    Facilitators: Mr Muti Abulafi, Consultant Colorectal Surgeon, Croydon University Hospital, Nigel D’Souza, Colorectal Research Fellow, Croydon University Hospital & Michelle Chen, Research Manager,RM Partners

12.50pm - Lunch

01.45pm - Roundtable - To fund or not to fund, this is the question

This interactive Roundtable will address current funding mechanisms in place to support the roll out and use of diagnostics in community healthcare. To prevent disease and illness the NHS must address the role Diagnostics can play, however without concise data and with tight budgets are we facing an uphill battle to change hearts and minds? Do we have the data to understand the true impact of diagnostics? Are we doing enough to promote the role of Diagnostics in a patient’s pathway? Should GPs be using diagnostics at point of care? 4 Panelists:
    Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre London School of Hygiene & Tropical Medicine - Confirmed
    Doris-Ann Williams, Chief Executive, BIVDA - Confirmed
    Dr Elisabeth Adams, Managing Director, Aquarius Population Health Limited - Confirmed
    Dr Vicki Chalker,Head, Respiratory and Vaccine Preventable Bacteria Reference Unit, National Infection Service, Public Health England - Confirmed

02.45pm - Case Study; Diagnostics in Action - Providing Access to Personalised Medicine by Improving Diagnostic Strategies

This presentation will highlight the centre’s research objectives to accelerate the embedding of personalised medicine as a routine part of cancer care for patients. The focus will be to develop molecular diagnostics and biomarkers for cancer to allow patient treatment to be personalised. Researchers aim to identify reliable biomarkers of disease prognosis or treatment response, and new molecular targets for a range of tumour types. This will drive the development of new cancer drugs.

Dr Michael Hubank, Head of Clinical Genomics (Research), The Royal Marsden Hospital - Confirmed

03.05pm - Case study; Diagnostics in action - HeadStart Programme - Care Pathway Modelling

MOLOGIC LTD, has developed a urine-based test system ‘HeadStart’ which enables chronic obstructive pulmonary disease (COPD) patients to monitor their disease status at home for early indications of exacerbation.

It will test the levels of key biomarkers in the urine, interpret them and identify imminent acute exacerbation and cause in 10 minutes. The NIHR DEC Newcastle is leading on the care pathway modelling work. The pathway descriptions will be developed through interviews with clinical experts. Whilst it is known that there is variability in practice throughout the UK, this study will focus on understanding the management of COPD within the Newcastle and North East area

Dr Michael Power, Deputy Director, NIHR DEC Newcastle- Confirmed

03.25pm - Case Study; Diagnostics in action - The Emergency Multidisciplinary Unit (EMU)

Rapid assessment from multiple healthcare disciplines (nursing, medicine, physiotherapy, occupational therapy, social care) provides comprehensive care delivery to address the multiple dimensions of need in this complex patient group.

Dr Daniel Lasserson GP and Professor of Ambulatory Care, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham - Confirmed

03.45pm - Closing keynote

Dr Tony Newman-Sanders, Clinical Director, Diagnostic Imaging, NHS England- Confirmed

04.05pm - Conference Close